Safety and efficacy of vibostolimab and pembrolizumab in patients with relapsed or refractory hematologic malignancies: A multicohort, open-label, phase 2 study

Category Primary study
JournalBlood
Year 2021
This article has no abstract
Epistemonikos ID: e94ca378fba4ccc1b2b1967594dff750f09ed140
First added on: Feb 13, 2025